DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Patten & Patten Inc. TN

Patten & Patten Inc. TN boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 77,958 shares of the medical device company’s stock after acquiring an additional 3,147 shares during the period. Patten & Patten Inc. TN’s holdings in DexCom were worth $5,324,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Congress Asset Management Co. grew its holdings in DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after acquiring an additional 1,332,522 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of DexCom during the 4th quarter worth approximately $5,812,000. SBI Securities Co. Ltd. purchased a new stake in shares of DexCom during the 4th quarter worth approximately $49,000. Asset Management One Co. Ltd. lifted its position in shares of DexCom by 3.4% during the 4th quarter. Asset Management One Co. Ltd. now owns 243,375 shares of the medical device company’s stock worth $19,528,000 after buying an additional 7,901 shares during the last quarter. Finally, MFG Wealth Management Inc. purchased a new stake in shares of DexCom during the 4th quarter worth approximately $1,574,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Down 1.4%

DXCM stock opened at $85.61 on Thursday. The company has a fifty day moving average price of $75.64 and a 200 day moving average price of $78.89. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $120.48. The company has a market cap of $33.57 billion, a price-to-earnings ratio of 59.87, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 earnings per share. Sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on DXCM. Mizuho began coverage on shares of DexCom in a research report on Thursday, April 10th. They set an “outperform” rating and a $85.00 price objective for the company. Canaccord Genuity Group boosted their price objective on shares of DexCom from $103.00 to $106.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. Citigroup restated a “buy” rating and set a $102.00 price objective (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Morgan Stanley boosted their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Finally, Cfra Research upgraded shares of DexCom to a “hold” rating in a research report on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.32.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 7,000 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the transaction, the executive vice president now directly owns 135,482 shares of the company’s stock, valued at approximately $10,002,636.06. The trade was a 4.91% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 32,498 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares in the company, valued at $26,183,401.02. This represents a 8.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 83,110 shares of company stock valued at $6,103,505. 0.32% of the stock is owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.